Identification of hub genes and therapeutic siRNAs to develop novel adjunctive therapy for Duchenne muscular dystrophy-Reference-Cited by-同舟云学术

Identification of hub genes and therapeutic siRNAs to develop novel adjunctive therapy for Duchenne muscular dystrophy

Published:2022-10-28 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Li Na¹,Zhikai Xiahou¹,Li Zhuo¹,Zhang Zilian¹,Song Yafeng¹

Affiliation:

1. Beijing Sport University

Abstract

Abstract Objective. Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder caused by various defects in the dystrophin gene and still no universal therapy. This study aims to identify the hub genes unrelated to excessive immune response but responsible for DMD progression and explore therapeutic siRNAs, thereby providing a novel treatment. Methods. Top ten hub gene for DMD were identified from GSE38417 dataset by using GEO2R and PPI network based on Cytoscape analysis. The hub genes unrelated to excessive immune response were identified by GeneCards, and their expression was further verified in mdx and C57 mice at 2 and 4 months (M) by (RT-q) PCR and western bloting. Therapeutic siRNAs were deemed as those that could normalized the expression of the validated hub genes in transfected C2C12 cell. Results. 855 up-regulated and 324 down-regulated DEGs were screened from GSE38417 dataset. Five of the top 10 hub genes were considered as the candidate genes unrelated to excessive immune response, and three of these candidates were consistently and significantly up-regulated in mdx mice at 2M and 4 M when compared with age-matched C57 mice, including Col1a2, Fbn1and Fn1. Furthermore, the three validated up-regulated candidate genes can be significantly down-regulated by three rational designed siRNA (p<0.0001), respectively. Conclusion. COL1A2, FBN1, and FN1 may be novel biomarkers for DMD, and the siRNAs designed in our study were help to develop adjunctive therapy for Duchenne muscular dystrophy.

Publisher

Research Square Platform LLC

Reference55 articles.

1. D. C. C. M. 1998. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans;FIRE* ANDREW;Nature

2. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping;ANTHONY K;JAMA neurology,2014

3. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium;ASHBURNER M;Nature genetics,2000

4. Muscle fibrillin deficiency in Marfan's syndrome myopathy;BEHAN WMH;Journal of neurology, neurosurgery, and psychiatry,2003

5. BLADEN, C. L., SALGADO, D., MONGES, S., FONCUBERTA, M. E., KEKOU, K., KOSMA, K., DAWKINS, H., LAMONT, L., ROY, A. J., CHAMOVA, T., GUERGUELTCHEVA, V., CHAN, S., KORNGUT, L., CAMPBELL, C., DAI, Y., WANG, J., BARIŠIĆ, N., BRABEC, P., LAHDETIE, J., WALTER, M. C., SCHREIBER-KATZ, O., KARCAGI, V., GARAMI, M., VISWANATHAN, V., BAYAT, F., BUCCELLA, F., KIMURA, E., KOEKS, Z., VAN DEN BERGEN, J. C., RODRIGUES, M., ROXBURGH, R., LUSAKOWSKA, A., KOSTERA-PRUSZCZYK, A., ZIMOWSKI, J., SANTOS, R., NEAGU, E., ARTEMIEVA, S., RASIC, V. M., VOJINOVIC, D., POSADA, M., BLOETZER, C., JEANNET, P.-Y., JONCOURT, F., DÍAZ-MANERA, J., GALLARDO, E., KARADUMAN, A. A., TOPALOĞLU, H., EL SHERIF, R., STRINGER, A., SHATILLO, A. V., MARTIN, A. S., PEAY, H. L., BELLGARD, M. I., KIRSCHNER, J., FLANIGAN, K. M., STRAUB, V., BUSHBY, K., VERSCHUUREN, J., AARTSMA-RUS, A., BÉROUD, C. & LOCHMÜLLER, H. 2015. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Human mutation, 36, 395–402.